John P. Shannon's most recent trade in Xeris Biopharma Holdings Inc was a trade of 36,918 Common Stock done at an average price of $5.4 . Disclosure was reported to the exchange on Aug. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. | 01 Aug 2025 | 36,918 | 2,657,425 (9%) | 0% | 5.4 | 198,619 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 800,000 | 2,687,118 (9%) | 2% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 600,000 | 600,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,997,868 (7%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,887,118 (6%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 39,443 | 2,108,618 (7%) | 0% | 3.6 | 142,389 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 300,000 | 300,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 250,000 | 2,419,612 (8%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.46 per share. | 29 Jan 2022 | 110,750 | 2,148,061 (7%) | 0% | 2.5 | 272,445 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 29 Jan 2022 | 41,334 | 2,355,089 (8%) | 0% | 1.1 | 46,294 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 29 Jan 2022 | 40,834 | 2,280,961 (8%) | 0% | 2.2 | 91,468 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 29 Jan 2022 | 23,414 | 2,331,675 (8%) | 0% | 1.3 | 29,502 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 29 Jan 2022 | 22,150 | 2,258,811 (8%) | 0% | 2.7 | 58,919 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 15,692 | 2,403,920 (8%) | 0% | 2.1 | 33,110 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 29 Jan 2022 | 9,880 | 2,321,795 (8%) | 0% | 1.2 | 12,251 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 7,497 | 2,396,423 (8%) | 0% | 2.1 | 15,819 | Common Stock |